Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Chubb
Daiichi Sankyo
Argus Health
AstraZeneca
Federal Trade Commission

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 7,378,426

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,378,426
Title:Fused heterotricyclic compounds as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3
Abstract: Disclosed are fused heterotricyclic compounds of the following formula I, ##STR00001## or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 3 (17.beta.-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
Inventor(s): Gavai; Ashvinikumar V. (Princeton Junction, NJ), Norris; Derek J. (Pennington, NJ), Han; Wen-Ching (Newtown, PA), Vite; Gregory D. (Titusville, NJ), Fink; Brian E. (West Windsor, NJ), Tokarski; John S. (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/066,407
Patent Claims:see list of patent claims

Details for Patent 7,378,426

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) ➤ Sign Up RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
Fuji
Moodys
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.